Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viridian Therapeutics, Inc.

15.88
+0.21001.34%
Post-market: 15.930.0500+0.31%19:27 EDT
Volume:708.75K
Turnover:11.18M
Market Cap:1.30B
PE:-4.77
High:15.93
Open:15.22
Low:15.18
Close:15.67
Loading ...

Viridian Therapeutics Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios

Reuters
·
07 Jun

Viridian Therapeutics Announces New Stock Option Grants as Inducement for New Employee Under Nasdaq Rule

Reuters
·
05 Jun

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Jun

Viridian Therapeutics Inc. to Present at Jefferies Global Healthcare Conference in New York

Reuters
·
30 May

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Viridian Therapeutics (VRDN)

TIPRANKS
·
26 May

Viridian Therapeutics announces long-term durability data from THRIVE trial

TIPRANKS
·
20 May

Viridian Therapeutics Unveils Strategic Presentation on Advancing Next-Generation Therapeutics and Pipeline Progress

Reuters
·
20 May

Viridian Therapeutics Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review

Reuters
·
20 May

Viridian Therapeutics: Positive Long-Term Durability Data From Veligrotug Phase 3 Thrive Clinical Trial

THOMSON REUTERS
·
20 May

Viridian Therapeutics: Preparing for Planned U.S. Commercial Launch of Veligrotug in 2026

THOMSON REUTERS
·
20 May

Viridian Therapeutics Inc: Bla Submission for Veligrotug Is on Track for H2 2025

THOMSON REUTERS
·
20 May

Viridian Therapeutics- Veligrotug Met All Primary and Secondary Endpoints in Pivotal Thrive and Thrive-2 Clinical Trials in Active and Chronic Ted

THOMSON REUTERS
·
08 May

Viridian Therapeutics- Bla Submission for Veligrotug on Track for Second Half 2025 With a Planned U.S. Launch in 2026, IF Approved

THOMSON REUTERS
·
08 May

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (Ted)

THOMSON REUTERS
·
08 May

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
07 May

Viridian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

Earnings Flash (VRDN) Viridian Therapeutics Posts Q1 Net Loss $0.87 a Share, vs. FactSet Est of $1 Loss

MT Newswires Live
·
06 May

BRIEF-Viridian Therapeutics Q1 Net Income USD -86.912 Million

Reuters
·
06 May

Viridian Therapeutics - Cash Position of $636.6 Mln as of March 31, 2025, Which Supports Cash Runway Into Second Half of 2027

THOMSON REUTERS
·
06 May

Viridian Therapeutics Q1 Cash & Investments USD 636.6 Million

THOMSON REUTERS
·
06 May